At just 25, Anastasia Sevriukova was diagnosed with stage 4 colon cancer after experiencing rectal bleeding. Now she’s sharing her story to encourage younger people not to dismiss persistent symptoms.
@thecancersurvivorsclub.com
@thecancersurvivorsclub.comAt just 25, Anastasia Sevriukova was diagnosed with stage 4 colon cancer after experiencing rectal bleeding. Now she’s sharing her story to encourage younger people not to dismiss persistent symptoms.
@thecancersurvivorsclub.comDr Lorrie Basnight spent decades caring for patients before suddenly finding herself on the other side of medicine following a breast cancer diagnosis. Her experience has changed how she thinks about cancer care.
@thecancersurvivorsclub.comFor certain cancers, stereotactic body radiation therapy can precisely target a tumour in as few as one to five treatments, reducing the burden of repeated hospital visits.
@thecancersurvivorsclub.comFDA oncology approvals between July and September expanded options for pancreatic, breast, lung, skin, kidney, bile duct and blood cancers, as well as some solid tumours with specific genetic alterations.
@thecancersurvivorsclub.comCancer-fighting T cells can become exhausted before the job is done. Scientists have identified a way to help them conserve energy and keep fighting for longer, potentially improving several forms of immunotherapy.
@thecancersurvivorsclub.comCAR-T research continues to push into solid tumours. A second patient has now received the highest dose being studied in a Phase 1 trial of an experimental FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
@thecancersurvivorsclub.comBreast cancer treatment is becoming increasingly personal. Tumour genomics can identify who may benefit from intensive treatment while targeted approaches such as antibody-drug conjugates aim treatment more directly at cancer cells.
@thecancersurvivorsclub.comLess treatment could still bring meaningful relief. Ultra-low-dose radiation given in just one or two sessions controlled painful bone lesions without further radiation in 81% of evaluable multiple myeloma patients in a trial.
@thecancersurvivorsclub.comFive major Phase 3 trials reported encouraging results in September, including advances in lung cancer and multiple myeloma and longer-term evidence for targeted treatment after lung cancer surgery.
@thecancersurvivorsclub.comSeptember brought a remarkable wave of progress in cancer care, with 10 FDA decisions covering breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus advances in brain tumour imaging.
@thecancersurvivorsclub.comA wonderful story of recovery. After being diagnosed with acute lymphoblastic leukaemia, Leila Macy received targeted treatment and immunotherapy. Tests now show no detectable residual leukaemia!
@thecancersurvivorsclub.comFewer hospital visits for prostate cancer patients? A study found that 25 radiotherapy sessions after surgery achieved similar five-year cancer control to 37 sessions.
@thecancersurvivorsclub.comEncouraging news for patients with advanced stomach cancer. New FDA-approved treatment combinations using zanidatamab offer additional first-line options for certain HER2-positive cancers.
@thecancersurvivorsclub.comMaking cancer treatment less frightening for children. Following the first paediatric treatments using upright proton therapy, Leo Cancer Care is developing interactive experiences to help young patients!
@thecancersurvivorsclub.comRadiotherapy could become faster and more convenient. Siemens Healthineers has unveiled Accela, a new system designed to deliver precise stereotactic treatments in as little as 60 seconds.
@thecancersurvivorsclub.comA new ovarian cancer trial is testing a different way to harness the immune system. NTB-928 is designed to redirect a patient’s own T cells to recognise and attack cancer cells.
@thecancersurvivorsclub.comAnother treatment option for advanced breast cancer. The FDA has approved imlunestrant plus abemaciclib for certain patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic disease.
@thecancersurvivorsclub.comSometimes hope means travelling 1,700 miles to find the care you need. After a gynecologic cancer diagnosis and limited access to specialist treatment, Nan Magdits travelled across the US in search of another chance.
@thecancersurvivorsclub.comEncouraging results in HER2-mutant lung cancer. Enhertu achieved median progression-free survival of 14.3 months versus 8.3 months with chemotherapy plus immunotherapy in DESTINY-Lung04.
@thecancersurvivorsclub.comProstate cancer treatment is becoming increasingly personalized. Genetic testing, targeted treatments, radioligand therapy and emerging immunotherapies are helping doctors match treatment more closely to individual cancers.